NOV 01, 2017 5:59 PM PDT

The Problems & Potential of Precision Medicine

WRITTEN BY: Carmen Leitch

In cancer diagnostics and therapeutics, genetic testing is used to guide doctors to the best treatments and most effective drugs for patients. This so-called precision medicine aims to identify genetic mutations that are driving cancer development and the targeted drugs that can treat them. A study by led by the Translational Genomics Research Institute (TGen) and the Keck School of Medicine of the University of Southern California (USC) has found that such medicine is actually not that precise when used for more diverse populations.

Researchers have found that genetic testing will likely benefit certain populations preferentially, and have developed a tool to try to address that problem. / Image credit: Maxpizel

In an ideal situation, a tumor from a patient as well as a sample of normal tissue is used to identify mutations that are tumor-specific. But a healthy sample is not always available, and genetic material from only the tumor is obtained. Population databases then have to be used to fill in for a normal sample, rather than healthy patient DNA. Because so much more population data is available for those of European ancestry, this approach is far less precise when applied to those of Latin American, African and Asian descent, according to work in the journal BMC Medical Genomics.

The research team wanted to create a computational tool to find variations in the genome that may cause cancer, so there will be an alternative to looking at population data only. Their new tool, LumosVar, is a big improvement, but cannot yet identify the ideal drugs for each individual with cancer.

"The field of precision medicine isn't taking into account population differences. The approaches being used are imprecise when you look at very specific populations," explained a lead author of the work, Dr. John Carpten, Director of the Institute of Translational Genomics at the Keck School of Medicine of USC.

"It is very difficult to identify a somatic, or potentially cancer-causing, variant when you don't have a germline, or normal, sample," said Dr. Rebecca Halperin, a TGen Assistant Research Professor and the other lead author. "It's even worse, depending on your ancestry. You get more false positives -- those genetic variants that don't cause cancer -- from populations with non-European ancestry."

Not only has most genetic data come from those of European descent, European ancestry is the least diverse. The most diverse genomes come from those in Bangladesh, while the least diverse come from Scandinavia, not necessarily a surprising finding when one considers geography. Sequencing more individuals from more areas will be necessary; there is, even more, work to be done.

"Simply sequencing more individuals from various populations is not enough. We really need access to the germlines. But when those aren't available, we need better tools and this is where we have put our focus," stressed Dr. David W. Craig, Vice Chair of the Keck School of Medicine of USC's Department of Translational Genomics and the study's senior author.

"There is a growing body of knowledge on the shortfalls of Precision Medicine," noted Dr. Rick Kittles, Professor and Founding Director of the Division of Health Equities, Department of Population Sciences, at City of Hope, and one of the world's foremost scientists in the area of population genetics and cancer.

This problem is a serious one; patients risk misdiagnosis. "That means you might be getting the wrong therapy simply because of our lack of understanding of the genetic architecture based on one's ancestry," Dr. Craig said. "These findings argue that we're really not doing a very good job of doing Precision Medicine for many populations."

"Tumor-only sequencing in patients from populations that have undergone rapid expansion significantly decreases the precision of Precision Medicine,” added Dr. Carpten. Importantly, the greater impact will be on individuals from underrepresented communities."

The LumosVar tool has been made openly accessible so that researchers and doctors can use it if they are looking for cancer-causing mutations. It is one step towards improving our ability to identify mutations that cause cancer rapidly so they can be targeted.


Learn more about precision medicine from the video by UCSF.

Sources: AAAS/Eurekalert! Via TGen, BMC Medical Genomics

About the Author
  • Experienced research scientist and technical expert with authorships on 28 peer-reviewed publications, traveler to over 60 countries, published photographer and internationally-exhibited painter, volunteer trained in disaster-response, CPR and DV counseling.
You May Also Like
JAN 30, 2020
Microbiology
JAN 30, 2020
25% of Antibiotic-Resistant Bacteria Can Spread Resistance Directly to Other Microbes
This research also suggests that antibiotics do not increase the rate at which bacteria acquire drug resistance genes....
FEB 17, 2020
Microbiology
FEB 17, 2020
Giant Viruses Blur the Line Between Life and Non-Life
Bacteriophages, also known as phages, are more complex than many viruses that we know of, and often carry large genomes....
MAR 17, 2020
Genetics & Genomics
MAR 17, 2020
Targeting RNA With CRISPR
Researchers screened thousands of target molecules to find the most effective targets, and have made their data openly available....
MAR 04, 2020
Neuroscience
MAR 04, 2020
Memories Are Stored As Specific Neural Firing Patterns
Scientists working on the EPFL Blue Brain Project explain the algebraic patterns of neuron activity.  Scientists at the National Institute of Health&r...
MAR 30, 2020
Genetics & Genomics
MAR 30, 2020
Scientists Discover an Antibiotic Resistance Gene
The gene enables bacteria to resist the effects of an aminoglycoside antibiotic called plazomycin....
APR 05, 2020
Genetics & Genomics
APR 05, 2020
Gene Variants Impact Natural Sunscreen & Vitamin D Levels
Vitamin D deficiencies have been linked to a variety of chronic diseases including bone disorders and heart disease....
Loading Comments...